SAB Biotherapeutics, Inc.
NASDAQ:SABS
3.51 (USD) • At close November 8, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue
| 2.239 | 23.904 | 60.876 | 55.238 | 3.442 |
| Cost of Revenue
| 3.745 | 3.292 | 1.654 | 0 | 0 |
| Gross Profit
| -1.506 | 20.612 | 59.222 | 55.238 | 3.442 |
| Gross Profit Ratio
| -0.673 | 0.862 | 0.973 | 1 | 1 |
| Reseach & Development Expenses
| 16.515 | 36.439 | 57.184 | 27.909 | 8.02 |
| General & Administrative Expenses
| 23.799 | 16.383 | 17.086 | 6.772 | 4.096 |
| Selling & Marketing Expenses
| -3.745 | 0 | 0 | 0 | 0 |
| SG&A
| 20.054 | 16.383 | 17.086 | 6.772 | 4.096 |
| Other Expenses
| 0 | -23.904 | -60.876 | 0.004 | 0.003 |
| Operating Expenses
| 36.569 | 28.918 | 13.393 | 34.681 | 12.115 |
| Operating Income
| -38.075 | -28.918 | -13.393 | 20.557 | -8.674 |
| Operating Income Ratio
| -17.006 | -1.21 | -0.22 | 0.372 | -2.52 |
| Total Other Income Expenses Net
| -4.118 | 10.202 | -3.751 | -0.439 | -0.313 |
| Income Before Tax
| -42.194 | -18.715 | -17.145 | 20.118 | -8.986 |
| Income Before Tax Ratio
| -18.845 | -0.783 | -0.282 | 0.364 | -2.611 |
| Income Tax Expense
| -0 | 0.026 | 0.3 | 0.473 | 0.431 |
| Net Income
| -42.194 | -18.741 | -17.444 | 20.118 | -9.417 |
| Net Income Ratio
| -18.845 | -0.784 | -0.287 | 0.364 | -2.736 |
| EPS
| -7.64 | -4.31 | -6.38 | 7.92 | -0.22 |
| EPS Diluted
| -7.64 | -4.31 | -6.38 | 7.45 | -0.22 |
| EBITDA
| -34.33 | -27.159 | -11.711 | 21.135 | -8.234 |
| EBITDA Ratio
| -15.333 | -1.136 | -0.192 | 0.383 | -2.392 |